Market Spotlight: Uterine Fibroids
Market Spotlight: Uterine Fibroids
$1,318.00
This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were approximately 94.9 million prevalent cases of uterine fibroids worldwide in females aged 15 years and over, and forecasts that number to increase to 105.0 million prevalent cases by 2028.
- Lupron, Orgovyx, and ORIAHNN, which target gonadotropin-releasing hormone receptor, and ulipristal acetate, which targets progesterone receptor, are the only approved drugs for uterine fibroids. These drugs are administered via the oral and subcutaneous routes.
- The largest proportion of industry-sponsored drugs in active clinical development for uterine fibroids are in Phase III, with one drug in the NDA/BLA phase.
- Therapies in development for uterine fibroids focus on targets such as progesterone receptor, gonadotropin-releasing hormone receptor, and collagen. The majority of pipeline drugs are administered via the oral route, with one product being developed in a subcutaneous formulation.
- High-impact upcoming events for drugs in the uterine fibroids space comprise expected CHMP opinions for Yselty and Orgovyx, as well as a PDUFA date for Orgovyx.
- The overall likelihood of approval of a Phase I gynecology asset is 11.9%, and the average probability a drug advances from Phase III is 70%. Drugs, on average, take 11.8 years from Phase I to approval, compared to 13.0 years in the overall obstetrics/gynecology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for uterine fibroids have been in the early and mid-phases of development, with 60% of trials in Phase I–II, and 40% in Phase III–IV.
- The US has a substantial lead in the number of uterine fibroids clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the uterine fibroids space is dominated by completed trials. Repros Therapeutics has the highest number of completed clinical trials for uterine fibroids, with 17 trials.
- Repros Therapeutics leads industry sponsors with the highest overall number of clinical trials for uterine fibroids, followed by Takeda.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Surgery
9 Medical agents
10 EPIDEMIOLOGY
13 MARKETED DRUGS
15 PIPELINE DRUGS
19 RECENT EVENTS AND ANALYST OPINION
19 Orgovyx for Uterine Fibroids (March 24, 2021)
20 Yselty for Uterine Fibroids (July 6, 2020)
23 Yselty for Uterine Fibroids (December 9, 2019)
27 KEY UPCOMING EVENTS
28 KEY REGULATORY EVENTS
28 New EU Filings
28 EMA’s CHMP Makes Decision On Esmya
28 EMA Safety Panel Recommends Withdrawing Esmya Authorizations
28 Myovant’s Relugolix Chases AbbVie’s Elagolix In Women’s Health Market
29 FDA Approves First Medical Treatment For Fibroid-Related Heavy Menstrual Bleeding
29 Myovant Sciences’ Relugolix Among 14 New Hopefuls At EMA
30 PROBABILITY OF SUCCESS
31 LICENSING AND ASSET ACQUISITION DEALS
31 Pfizer Gains New Commercial Drug Orgovyx In Deal With Myovant
31 Hologic Acquires Acessa To Add ProVu Fibroid Treatment
31 Myovant Licenses Ex-US Relugolix Rights To Gedeon Richter
32 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
36 Recent events
38 BIBLIOGRAPHY
39 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of uterine fibroids, 2019–28
15 Figure 2: Overview of pipeline drugs for uterine fibroids in the US
15 Figure 3: Pipeline drugs for uterine fibroids, by company
16 Figure 4: Pipeline drugs for uterine fibroids, by drug type
16 Figure 5: Pipeline drugs for uterine fibroids, by classification
20 Figure 6: Orgovyx for Uterine Fibroids (March 24, 2021): Phase III – Withdrawal (w/Estradiol + Norethindrone Acetate)
23 Figure 7: Yselty for Uterine Fibroids (July 6, 2020): Phase III – PRIMROSE 1
26 Figure 8: Yselty for Uterine Fibroids (December 9, 2019): Phase III – PRIMROSE 2
27 Figure 9: Key upcoming events in uterine fibroids
30 Figure 10: Probability of success in the gynecology pipeline
33 Figure 11: Clinical trials in uterine fibroids
33 Figure 12: Top 10 drugs for clinical trials in uterine fibroids
34 Figure 13: Top 10 companies for clinical trials in uterine fibroids
34 Figure 14: Trial locations in uterine fibroids
35 Figure 15: Uterine fibroids trials status
36 Figure 16: Uterine fibroids trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of uterine fibroids, 2019–28
14 Table 2: Marketed drugs for uterine fibroids
17 Table 3: Pipeline drugs for uterine fibroids in the US
19 Table 4: Orgovyx for Uterine Fibroids (March 24, 2021)
21 Table 5: Yselty for Uterine Fibroids (July 6, 2020)
24 Table 6: Yselty for Uterine Fibroids (December 9, 2019)
32 Table 7: Historical global sales, by drug ($m), 2016–20
32 Table 8: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL) 
Sign up to the